AN DER GOLDGRUBE 12, MAINZ, 2M
Advances Phase 3 Clinical Trial of Pumitamig in Combination with TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
Announces Appointment of New Independent Auditor
BioNTech and OncoC4 Show Gotistobart Doubles Survival in Lung Cancer
Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer
Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
Development Update and Financial Results for the Three and Six Months Ended June 30, 2026
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Tender Offer Statement by Third Party
No filings found
Statement of Changes in Beneficial Ownership
Amended Tender Offer Statement by Third Party
Amended Notice of Proposed Sale of Securities
S-8 POS